Product Overview
[Drug Name]
Generic Name: Isosorbide Mononitrate Tablets
Trade Name: Lizhu Xinle Isosorbide Mononitrate Tablets 10mg x 50 Tablets
[Main Ingredients]
The main ingredient of this product is isosorbide mononitrate.
[Properties]
This product is a white tablet.
[Indications/Main Functions]
For the long-term treatment of coronary heart disease, prevention of vasospastic and mixed angina, and for the treatment of post-myocardial infarction and long-term treatment of chronic heart failure.
[Specifications]
10mg x 50 tablets
[Dosage and Administration]
Oral. 10-20mg three times a day, or as directed by a physician.
[Adverse Reactions]
May cause headaches, facial flushing, burning sensation, nausea, dizziness, and sweating, but are generally mild.
[Contraindications]
Acute circulatory failure (shock, circulatory collapse); severe hypotension (systolic pressure <90 mmHg); acute myocardial infarction with low filling pressures (unless under continuous hemodynamic monitoring); hypertrophic obstructive cardiomyopathy; constrictive pericarditis or cardiac tamponade; severe anemia; glaucoma; increased intracranial pressure; hypersensitivity to nitro compounds.
[Drug Interactions]
Combination with other vasodilators, calcium antagonists, beta-blockers, antihypertensives, tricyclic antidepressants, and alcohol may potentiate the hypotensive effect of this drug class.
[Precautions]
Contraindicated in patients with severe hypotension, shock, and acute myocardial infarction. Use with caution during pregnancy.
[Pediatric Use]
Studies of this drug class have been conducted in adults. There are no data comparing its use in children and adults. Therefore, it is not recommended for use in children.
[Use in Elderly Patients]
Elderly patients may be more sensitive to this drug class and may be more susceptible to reactions such as dizziness.
[Overdose]
Data on human overdose are limited. The most likely manifestations of overdose would be hypotension and tachycardia. Due to parasympathetic (vagal) stimulation, bradycardia may occur. If symptomatic hypotension occurs, supportive care should be provided. Neither losartan nor its active metabolite can be eliminated by hemodialysis.
[Pharmacology and Toxicology]
Isosorbide mononitrate (ISMN) is the primary biologically active metabolite of isosorbide dinitrate. Like other organic nitrates, its primary pharmacological action is smooth muscle relaxation. ISMN releases nitric oxide (NO), which, like endothelial relaxing factor, activates guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle cells. This relaxes vascular smooth muscle and dilates peripheral arteries and veins, with a stronger venous dilation effect. Venous dilation causes blood to remain in the periphery, reducing venous return and lowering left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arterial dilation reduces peripheral vascular resistance, systolic arterial pressure, and mean arterial pressure (afterload), and coronary artery dilation increases coronary perfusion. The overall effect is to reduce myocardial oxygen consumption and increase oxygen supply.
